關於 yescarta ，我們在網路上蒐集到這些相關的討論、資訊與評價

#11. Definition of Yescarta - NCI Dictionary of Cancer Terms

A drug used to treat adults with follicular lymphoma or certain types of large B-cell lymphoma that relapsed (came back) or did not get better after ...

#12. Gilead's Kite matches Bristol Myers with Yescarta CAR-T win ...

The company reported encouraging data from a phase 2 trial of Yescarta in newly diagnosed lymphoma patients at last December's ASH annual ...

#13. Yescarta (axicabtagene ciloleucel) dosing, indications ...

Medscape - Refractory aggressive non-Hodgkin lymphoma dosing for Yescarta (axicabtagene ciloleucel) frequency-based adverse effects, ...

#14. Yescarta™ (axicabtagene ciloleucel) - Roswell Park

Yescarta is an FDA-approved immunotherapy — a treatment designed to help your own immune system fight cancer. Specifically, it is a type of chimeric antigen ...

#15. Yescarta cells dispersion for infusion - eMC

Yescarta is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell ...

#16. Early trial results indicate Yescarta CAR-T therapy improves ...

The study evaluated a one-time infusion of Yescarta compared with standard of care in patients who had relapsed or had refractory LBCL after frontline ...

#17. Yescarta: Uses, Dosage, Side Effects & Warnings - Drugs.com

Yescarta (axicabtagene ciloleucel) is an immunotherapy medicine used to treat large B-cell lymphoma and follicular lymphoma in adults.

#18. Yescarta (axicabtagene ciloleucel) | CenterWatch

Yescarta is specifically indicated for the treatment of the following: adult patients with relapsed or refractory large B-cell lymphoma after two or more lines ...

#19. YESCARTA® and TECARTUS® REMS

Risk Evaluation and Mitigation Strategy for YESCARTA® (axicabtagene ciloleucel) and TECARTUS® (brexucabtagene autoleucel). Downloadable resources for HCPs.

#20. YESCARTA- axicabtagene ciloleucel suspension - DailyMed

YESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: 1.1 Large B-cell Lymphoma - Adult patients with ...

#21. Yescarta reduces death risk by 73% in refractory large B-cell ...

Gilead Sciences' Yescarta (axicabtagene ciloleucel) demonstrated a high ORR and a 73 percent reduction in the risk of death in refractory ...

#22. Kite seeks expanded approval of Yescarta for large B-cell ...

Axicabtagene ciloleucel (Yescarta, Kite Pharma), a CD19-directed genetically modified autologous T-cell immunotherapy, is approved in the ...

#23. Gilead Files for FDA Approval of Second-Line Yescarta for ...

... for its autologous CAR T-cell therapy, axicabtagene ciloleucel (Yescarta) for second-line large B-cell lymphoma treatment.

#24. YESCARTA Dosage & Rx Info | Uses, Side Effects - eMPR.com

Leukemias, lymphomas, and other hematologic cancers: Indications for: YESCARTA. In adults with relapsed or refractory large B-cell lymphoma after 2 or more ...

#25. Yescarta Intravenous: Uses, Side Effects, Interactions, Pictures ...

Yescarta IV Suspension - Uses, Side Effects, and More. Generic Name(S): axicabtagene ciloleucel. View Free Coupon. Uses; Side Effects; Precautions ...

#26. Yescarta (Axicabtagene Ciloleucel ... - The Oncology Pharmacist

Yescarta Second Gene Therapy Approved by the FDA. On October 18, 2017, Yescarta (axicabtagene ciloleucel; Kite Pharma) was approved by the US Food and Drug ...

#27. Kite's CAR-T therapy Yescarta shows positive results in ...

The top-line results come from the phase 3 ZUMA-7 trial, which is investigating Yescarta (axicabtagene ciloleucel) compared to standard of care ...

#28. 1587 - YESCARTA™ (axicabtagene ciloleucel [KTE ... - MSAC

1587 - YESCARTA™ (axicabtagene ciloleucel [KTE-C19]) for the treatment of refractory or relapsed CD19-positive lymphoma · Announcement.

#29. The FDA approves Yescarta (axicabtagene ciloleucil) for ...

On 18th October 2017, the U.S. Food and Drug Administration (FDA) approved Kite Pharma's Yescarta (axicabtagene ciloleucil) for the treatment of relapsed or ...

#30. YESCARTA - Orphanet

YESCARTA. Axicabtagene ciloleucel. Marketing authorization with orphan designation - Europe. Diseases list. Primary mediastinal large B-cell lymphoma.

#31. Gilead's Kite earns second-line win for CAR-T Yescarta ...

Kite's Yescarta boosted event free survival over a standard of care regimen of physicians'-choice salvage therapy followed by high-dose chemo plus a stem ...

#32. Yescarta | FAMHP

Yescarta. Active substance. Axicabtagene ciloleucel. Holder. Gilead Sciences Belgium bvba. Status. Closed. Indication. Treatment of aggressive conditions in ...

#33. US FDA approves new indication for Yescarta - The Pharma ...

The approval makes Yescarta the first chimeric antigen receptor (CAR) T-cell therapy approved for patients with indolent follicular lymphoma ...

#34. YESCARTA (axicabtagène ciloleucel) - Haute Autorité de Santé

YESCARTA (axicabtagene ciloleucel) reste un traitement de 3 ème ligne ou plus du lymphome diffus à grandes cellules B (LDGCB) et du lymphome ...

#35. FICHA TECNICA YESCARTA 0,4 - 2 x 10e8 CELULAS ... - CIMA

Yescarta (axicabtagén ciloleucel) es una inmunoterapia de células T autólogas modificadas genéticamente dirigidas contra CD19. ... Las células T CAR positivas ...

#36. Axicabtagene ciloleucel (Yescarta) | HemOnc.org

Axicabtagene ciloleucel (Yescarta) · Contents · Mechanism of action · Diseases for which it is used · Patient Drug Information · History of changes ...

#37. Yescarta - LLS TAP supported FDA approval

KTE-C19 (Yescarta®, Axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy first approved by the U.S. Food and ...

#38. Gilead's (GILD) Kite Announces Positive Data on Yescarta

ZUMA-7 evaluated a one-time infusion of the CAR T-cell therapy Yescarta compared to the standard of care (SOC) in adult patients with relapsed ...

#39. 研究：Yescarta細胞療法淋巴瘤患者至少多活3年| 國際 - 中央社

根據一項新數據，接受美國藥廠「吉利德科學公司」（Gilead Sciences Inc）嵌合抗原受體T細胞（CAR-T）免疫療法Yescarta後，近半數淋巴瘤患者可多活 ...

#40. Gilead seals UK deal for Yescarta to treat patients by end of year

NHS England has approved CAR-T therapy Yescarta, placing Gilead one-step ahead of Novartis in the race to treat UK adult patients.

#41. Yescarta - Gene Therapy Net

Yescarta (axicabtagene ciloleucel) is a treatment for large B-cell lymphoma that has failed conventional treatment. T cells are removed from a person with ...

#42. 美國FDA核准Gilead和Kite Pharma癌症CAR-T治療Yescarta

The Food and Drug Administration approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, ...

#43. ZUMA-7 Results Underscore Yescarta's Efficacy for LBCL

ZUMA-7 results indicate axicabtagene ciloleucel (Yescarta) improves event-free survival among adult patients with second-line relapsed or ...

#44. Yescarta® (Axicabtagene Ciloleucel) Demonstrates High ...

Yescarta ® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma - read this ...

#45. Kite's YESCARTA® (Axicabtagene Ciloleucel ... - Newswire.ca

CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) announced today that YESCARTA® (axicabtagene ciloleucel) is now available in Alberta as ...

#46. Axicabtagene ciloleucel (Yescarta) Drug Information

Yescarta is approved for: Adults with follicular lymphoma, whose cancer did not respond (refractory) to treatment or responded to two or more ...

#47. Kymriah vs. Yescarta [UPDATED] | Nucleus Biologics

Kymriah & Yescarta are the only two FDA-approved CAR-T cell therapy products available in the US. This chart shows their similarities ...

#48. Yescarta Meets Endpoints in Second-line DLBCL - Formulary ...

Kite, a Gilead Company, has announced positive top-line results from the phase 3 ZUMA-7 trial of CAR T-cell therapy Yescarta (axicabtagene ...

#49. Yescarta (axicabtagene ciloleucel): Cancer Drug Side Effects ...

Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy used to treat adults with ...

#50. A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in ...

Other Name: Yescarta®. Drug: Cyclophosphamide. Administered intravenously. Drug: Fludarabine. Administered intravenously ...

#51. CAR-T therapy Yescarta get EU green light but meets ...

Yescarta ® (axicabtagene ciloleucel), a novel personalized CAR T cell therapy has been approved for use in Europe by the European Medicines ...

#52. YESCARTA - HPRA

YESCARTA. 0.4 - 2x10 8 cells Dispersion for infusion. Kite Pharma EU B.V.EU/1/18/1299/001. Main Information. Trade NameYESCARTA.

#53. Axicabtagene ciloleucel for treating diffuse large B-cell ... - NICE

Evidence-based recommendations on axicabtagene ciloleucel therapy (Yescarta) for treating diffuse large B-cell lymphoma and primary ...

#54. Axicabtagene Ciloleucel (Yescarta™) | OncoLink

Axicabtagene Ciloleucel (Yescarta™) is a CD19-directed genetically-modified autologous (self-directed) T cell immunotherapy cancer treatment used to treat ...

#55. Yescarta® Is First CAR T-cell Therapy to Demonstrate High ...

Yescarta ® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin ...

#56. FDA Approves Yescarta for Non-Hodgkin Lymphoma - GoodRx

This new treatment, Yescarta, is made from the patient's own white blood cells that are engineered recognize and attack the lymphoma cells.

#57. Kite's YESCARTA® (Axicabtagene Ciloleucel) Reimbursed in ...

Kite's YESCARTA® (Axicabtagene Ciloleucel) Reimbursed in Alberta for the Treatment of Certain Types of Aggressive Non-Hodgkin Lymphoma ...

#58. NHS England reaches deal with Gilead on CAR-T therapy ...

NHS England has reached an agreement with Gilead Sciences to provide CAR-T therapy Yescarta (axicabtagene ciloleucel) for adults with large ...

#59. Kite, Pfizer to Assess Yescarta-Utomilumab Combination in ...

“Kite is committed to realizing the full potential of Yescarta and other cell therapy technologies across a range of cancers,” David Chang, M.D. ...

#60. China granted first CAR T approval to Fosun-Kite's Yescarta

China's drug regulator granted a first CAR T therapy approval to Fosun Kite Biotechnology's FKC-876. Marketed as Yescarta (axicabtagene ciloleucel) in the ...

#61. Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell ...

On October 18, 2017, Yescarta (axicabtagene ciloleucel; Kite Pharma) was approved by the US Food and Drug Administration (FDA) for the ...

#62. Yescarta (axicabtagene ciloleucel) for Large B-Cell Lymphoma

Yescarta ™ (axicabtagene ciloleucel) is one of the first CAR T therapies indicated for the treatment of relapsed/refractory large B-cell lymphoma in adults.

#63. Axicabtagene Ciloleucel (Yescarta) CAR T-Cell Therapy

Axicabtagene Ciloleucel (Yescarta) CAR T-Cell Therapy side effects, how it's given, how it works, precautions and self care tips in treatment of lymphoma.

#64. Yescarta (Axicabtagene Ciloleucel) - Side Effects, Interactions ...

Find everything you need to know about Yescarta (Axicabtagene Ciloleucel), including what it is used for, warnings, reviews, side effects, ...

#65. Gilead gains CAR-T approval, undercuts rival's headline price -

Gilead's CAR-T cancer therapy Yescarta has been approved in the US for an aggressive form of blood cancer, indicating the company's $12 ...

#66. Yescarta becomes first CAR-T therapy approved in China

This week Yescarta® (axicabtagene ciloleucel) has been approved as the first CAR-T therapy in China for patients with large B-cell lymphoma.

#67. Yescarta First CAR T-Cell Therapy Approved for Follicular ...

On March 5, 2021, the FDA approved a new indication for axicabtagene ciloleucel (Yescarta; Kite Pharma), a chimeric antigen receptor (CAR) T-cell therapy, ...

#68. 當代醫藥法規月刊第94期

Axicabtagene ciloleucel (YESCARTA ® ) US FDA 2017 年核准仿單。 5. Axicabtagene ciloleucel (YESCARTA ® ) US FDA 藥毒理(Ref. 5-1)以及臨床(Ref.

#69. Gilead's cell therapy Yescarta awarded FDA approval for ...

FDA approval for Yescarta in follicular lymphoma makes it the first approved CAR-T treatment for this type of cancer. It also marks Gilead ...

#70. CAR T-cell therapy Yescarta® not available in Scotland

The Scottish Medicines Consortium (SMC) has today (11 February 2019) announced that the CAR T-cell therapy axicabtagene ciloleucel (Yescarta®) is not ...

#71. COMPLETE REMISSION IS POSSIBLE - Lymphoma ...

YESCARTA ® is different than other cancer medicines because it is made from your own white blood cells, which have been modified to recognize and attack your ...

#72. YESCARTA - OMEDIT Ile de France

YESCARTA · Axicabtagene ciloleucel DCI · Fiche(s) Juste Prescription · Domaine(s) thérapeutique(s) · Générique(s) / Biosimilaire(s).

#73. What You Need to Know Today About Yescarta - Moffitt ...

Yescarta indications: certain types of large B-cell lymphoma; refractory or relapsed patients.

#74. New CAR T Cell Therapy option now available in Australia for ...

Eligible patients can now access Yescarta through Royal Brisbane and Women's Hospital, Brisbane and the Peter MacCallum Cancer Centre, ...

#75. Frequently Asked Questions About YESCARTA ...

YESCARTA is a genetically-modified autologous T-cell immunotherapy. Chimeric Antigen Receptor (CAR) T-cell therapy is a new type of treatment ...

#76. NICE says 'no' to Gilead's Yescarta in draft guidelines

NHS funding for Gilead's freshly approved CAR-T therapy Yescarta has been turned down in draft guidelines by the National Institute for ...

#77. CAR-T Cell Therapy Approval Gilead Kite Yescarta - Business ...

The treatment, called Yescarta, treats a type of blood cancer called aggressive B-cell non-Hodgkin lymphoma.

#78. Kite Announces Two-Year Data for Yescarta® (Axicabtagene ...

In October 2017, Yescarta became the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug ...

#79. Yescarta Second Gene Therapy Approved by FDA and First ...

On October 18, 2017, the FDA approved axicabtagene ciloleucel (Yescarta; Kite Pharma), a CD19-directed genetically modified CAR T-cell immunotherapy, ...

#80. Gilead reaches deal for Yescarta coverage in England

Yescarta will now be included in NHS England's Cancer Drugs Fund, which provides managed access to new treatments while additional evidence is ...

#81. Axicabtagene Ciloleucel (Yescarta®) - BlueCross BlueShield ...

Axicabtagene Ciloleucel (Yescarta®) · DESCRIPTION. Axicabtagene ciloleucel is a CD19-directed genetically modified autologous T cell ...

#82. ID2019_143 Axicabtagene ciloleucel (Yescarta) for the ...

Axicabtagene ciloleucel (Yescarta) for the treatment of second or later relapsed/refractory diffuse large B cell.

#83. Lymphoma patients to benefit from new cancer therapy

Yescarta (axicabtagene ciloleucel) is a type of CAR-T cell therapy that is used to treat patients with certain types of lymphoma—a form of ...

#84. Yescarta - PMLiVE

Latest news and features about Yescarta - for people working in pharma, biotech and healthcare industries.

#85. YESCARTA® Approved in Japan for Treatment of Patients ...

YESCARTA has been approved in Japan for treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, primary mediastinal ...

#86. YESCARTA™ - Hematology Oncology Associates of ...

For which conditions is this drug approved? YESCARTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphomas after ...

#87. A Cutting-Edge Immunotherapy Treatment Was Just Approved ...

The FDA said the safety and efficacy of Yescarta were established in a multi-centre trial of more than 100 adults with large B-cell lymphoma. " ...

#88. Yescarta: A New Era for Non-Hodgkin Lymphoma Patients

Yescarta was the second anti-cancer gene therapy approved in the year 2017 by the FDA. This gene therapy is focused on genetically altering a ...

#89. Pakketadvies sluisgeneesmiddel axicabtagene ciloleucel ...

Pakketadvies sluisgeneesmiddel axicabtagene ciloleucel (Yescarta®) voor volwassenen met recidiverend of refractair DLBCL en PMBCL na 2 of meer ...

#90. Yescarta: Side effects, alternatives, uses, dosage, and more

Yescarta (axicabtagene ciloleucel) is a prescription drug used for large B-cell lymphoma, a type of non-Hodgkin lymphoma.

#91. Axicabtagene Ciloleucel (Yescarta) - Aetna

On October 18, 2017, the U.S. Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) for the treatment of adults with relapsed or ...

#92. FDA Approves Yescarta (Axicabtagene Ciloleucel) for Adults ...

The US Food and Drug Administration (FDA) has approved Yescarta (axicabtagene ciloleucel) to treat adults with certain types of large B-Cell ...

#93. FDA Approves Yescarta for Third-Line Treatment of Relapsed ...

Kite Pharma announced that Yescarta (axicabtagene ciloleucel) has been granted accelerated approval by the Food and Drug Administration ...

#94. axicabtagene ciloleucel (Yescarta) - Scottish Medicines ...

axicabtagene ciloleucel (Yescarta®) is accepted for use within NHSScotland. Indication under review: Treatment of adult patients with ...

#95. 定价37.3万美元第二款CAR-T细胞药物Yescarta获批 - 新浪医药

10月19日，距Gilead以120亿美元完成对Kite Pharma的收购刚刚两周时间。美国FDA宣布批准了Kite Pharma的CAR-T疗法Yescarta(axicabtagene ciloleucel) ...

#96. Yescarta (Axicabtagene Ciloleucel)* - Wellmark

Yescarta (Axicabtagene ciloleucel) is currently FDA approved and indicated in the treatment of adult patients with relapsed or refractory large B-cell lymphoma ...

#97. Yescarta Shows Promise in Advanced Non-Hodgkin ...

Yescarta (axicabtagene ciloleucel), Kite Pharma's CAR T-cell therapy, leads to a high rate of strong and sustained responses in adults with ...

#98. FDA Approves Yescarta™, Revolutionary CAR-T ...

Yescarta is a Chimeric Antigen Receptor (CAR) T cell therapy, also known as CAR-T. Moffitt Cancer Center's Frederick Locke, M.D., is the co-lead ...